The Genome Analysis Unit (GAU) is seeking a talented computational biologist to join our team and further our mission of making biological discoveries that accelerate and enable drug discovery at Amgen. The Scientist will be part of the computational biology group in the GAU, which operates semi-autonomously, as well as, collaboratively across all areas of Discovery Research. The position focuses on the application of bioinformatics expertise to the analysis and interpretation of large sequencing datasets, with particular emphasis on transcriptomics and RNA-Seq data.
Apply advanced techniques in bioinformatics, statistical analysis, and programming to biological problems across a wide range of human disease areas at Amgen.
Work with large biological data sets including Next Generation Sequencing (NGS) data (RNA-Seq, Genome/Exome-Seq, etc.), with particular emphasis on analysis of RNA-Seq datasets to explore drug target biology, inform liability assessments, and characterize transcript variants.
- Doctorate degree
- Master’s degree and 4 years of scientific experience
- Bachelor’s degree and 6 years of scientific experience
- An advanced degree in Bioinformatics, Biostatistics, Computer Science, Genomics, or other related field.
- Hands-on experience in the fields of bioinformatics and genomics including working with various public and proprietary data repositories (e.g., TCGA, GTEx, dbSNP, Ensembl, UCSC genome browser, Array Studio), bioinformatics tools (e.g., BLAST, samtools/GATK/picard), and statistical environments (e.g., R, S+, Matlab).
- Prior experience with interpretation and analysis of RNA-Seq data.
- Experience with manipulation, interpretation, and innovative analysis (e.g. novel algorithm development) of large biological datasets.
- Proficient in programming (e.g., Python, Java, C/C++) and working in a Unix/Linux environment, being able to develop customized bioinformatics tools.
- A strong background in biology, especially as it pertains to human disease in the fields of Oncology, Metabolic Disease, Neurological Disease, and Inflammation.
- Enthusiasm for interacting with bench scientists to develop new technologies and refine our approaches.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.